Stock PMN PROMIS NEUROSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ProMIS Neurosciences, Inc.

Equities

PMN

CA74346M4065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
1.94 USD -3.00% Intraday chart for ProMIS Neurosciences, Inc. +2.06% +68.70%
Apr. 30 ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies CI
Apr. 09 ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS CI

Business Summary

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

Number of employees: 7

Managers

Managers TitleAgeSince
Neil Warma CEO
 Chief Executive Officer 61 21-05-12
Neil Cashman FOU
 Founder 72 04-01-22
Eugene Williams CHM
 Chairman 64 15-06-28
Daniel Geffken DFI
 Director of Finance/CFO 67 17-03-21
Gavin Malenfant COO
 Chief Operating Officer 61 21-10-21
Larry Altstiel CTO
 Chief Tech/Sci/R&D Officer 74 22-04-18
Dennis Chen PRN
 Corporate Officer/Principal - -
David Wishart PRN
 Corporate Officer/Principal - 21-05-26
Ernest D. Bush PRN
 Corporate Officer/Principal - 18-04-02
Johanne Kaplan PRN
 Corporate Officer/Principal 64 16-07-20

Members of the board

Members of the board TitleAgeSince
William Wyman BRD
 Director/Board Member 86 14-03-07
Neil Cashman FOU
 Founder 72 04-01-22
Neil Warma CEO
 Chief Executive Officer 61 21-05-12
Eugene Williams CHM
 Chairman 64 15-06-28
Patrick Kirwin BRD
 Director/Board Member - 15-06-28
Josh Mandel-Brehm BRD
 Director/Board Member 41 21-08-31
Maggie Shafmaster BRD
 Director/Board Member 65 21-09-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 18,961,116 14,347,158 ( 75.67 %) 0 75.67 %

Shareholders

NameEquities%Valuation
Sphera Funds Management Ltd.
9.673 %
1,834,042 9.673 % 4 M $
Mike Gordon
6.112 %
1,158,846 6.112 % 2 M $
Ally Bridge Group HK Ltd
5.626 %
1,066,674 5.626 % 2 M $
Crocker Mountain LLC
5.304 %
1,005,726 5.304 % 2 M $
Jeremy Sclar
4.402 %
834,763 4.402 % 2 M $
Affinity Asset Advisors LLC
1.403 %
265,958 1.403 % 518 618 $
Eugene Williams
0.8435 %
159,930 0.8435 % 311 864 $
Neil Cashman
0.6061 %
114,921 0.6061 % 224 096 $
Northeast Financial Consultants, Inc.
0.5274 %
100,000 0.5274 % 195 000 $
Patrick Kirwin
0.4699 %
89,096 0.4699 % 173 737 $
NameEquities%Valuation
Mike Gordon
42.86 %
30,000,000 42.86 % 59 M $
NameEquities%Valuation
Mike Gordon
100.00 %
500,000 100.00 % 975 000 $
Jeremy Sclar
60.00 %
300,000 60.00 % 585 000 $

Company contact information

ProMIS Neurosciences, Inc.

1920 Yonge Street Suite 200

M4S 3E2, Toronto

+416 847 6898

http://www.promisneurosciences.com
address ProMIS Neurosciences, Inc.(PMN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.736 CAD
Average target price
12.02 CAD
Spread / Average Target
+339.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PROMIS NEUROSCIENCES, INC. Stock ProMIS Neurosciences, Inc.
+68.70% 37.92M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.33% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.11% 105B
BIONTECH SE Stock BioNTech SE
-12.56% 22.34B
ARGENX SE Stock argenx SE
-3.70% 21.93B
GENMAB A/S Stock Genmab A/S
-6.03% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.86% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.10% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.57% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PMN Stock
  4. Company ProMIS Neurosciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW